Latest news

Media Alert: successful registration after shortest ever review by the FDA of Eloxatin

Dyax Corp. and Debiopharm S.A. report successful results of phase IIA clinical trial with DX-890 for cystic fibrosis

Debiopharm S.A. inaugurates a new State-of-the-Art Galenic Unit in Gland, Switzerland

H3 Pharma announces promising developments for the treatment of Alzheimer´s disease

Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury

Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004

H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…

Swiss company Debio R.P. announces Agreement with Inhale subsidiary Shearwater Corporation

Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use